Studies low white blood cell counts from palbociclib in breast cancer
Observes low white blood cell counts in people with advanced breast cancer taking palbociclib.
Plain-language title generated from the registry record
Registry title: Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
Key facts
- Where
- Al Madīnah, Saudi ArabiaSee the site
Where in Saudi Arabia
- Asmaa Imam AhmedAl Madīnah, Saudi ArabiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assiut University
- Trial code
- NCT06076772
- Record updated
- 11 October 2023
- Original description
Aim of the study to assess the neutropenia induced by Palbociclib in patient receiving Palbociclib in combination with hormonal treatment as first-line therapy in metastatic hormone receptor- positive HER2 negative breast cancer. To evaluate the risk factors for occurrence of neutropenia and treatment outcome as 2 years PFS and OS.Read full original descriptionShow less
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients
Aim of the study to assess the neutropenia induced by Palbociclib in patient receiving Palbociclib in combination with hormonal treatment as first-line therapy in metastatic hormone receptor- positive HER2 negative breast cancer. To evaluate the risk factors for occurrence of neutropenia and treatment outcome as 2 years PFS and OS.
Inclusion: Histological pathological confirmation of primary breast cancer or metastatic disease; Hormonal receptor-positive, HER2 negative; Metastatic breast cancer at presentation (Den novo) or recurrent; Patients did not receive any previous systemic therapy for metastatic disease; Performance status (ECOG) 0-2.
Exclusion: Patient with co-morbidity; Pregnant and breast lactating women.